Abstract
Claire Liefferinckx, Bram Verstockt, Ann Gils, Sophie Tops, Wouter Van Moerkercke, Severine Vermeire and Denis Franchimont. Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. United European Gastroenterology Journal 2019; 7: 750–758. doi: 10.1177/2050640619841538.
On page 753, Figure 1 has incorrect values. The correct figure should read as below:
Flowchart of the overall population.
Legends remain unchanged.